rhenium (186Re) obisbemeda (REYOBIQ) — Topline data
2026
Current enrollment rates indicate full enrollment in 2026 followed by a data readout and a subsequent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA)Source filing
CNSY biotech catalysts & pipeline
CERENOME INC · Data as of 2026-09-08
Upcoming catalysts
rhenium (186Re) obisbemeda (REYOBIQ) — Topline data
Late 2026
We completed Phase 1 of our ReSPECT-GBM Trial and are targeting full enrollment into Phase 2 by the end of 2026.Source filing
rhenium (186Re) obisbemeda (REYOBIQ) — Topline data
Q1 2027
Complete enrollment in the ReSPECT-GBM Phase 2 trial for glioblastoma; data is expected in Q1 2027, followed by an End-of-Phase 2 meeting with the FDASource filing